Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A221208||Alliance||Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases||Cancer Prevention and Control CIRB||Available to Open|
|A031801||Alliance||A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A211401||Alliance||Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes||Cancer Prevention and Control CIRB||Available to Open|
|A171601||Alliance||A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer||Cancer Prevention and Control CIRB||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031102||Alliance||A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|A231601CD||Alliance||Improving Surgical Care and Outcomes In Older Cancer Patients Through Implementation of An Efficient Pre-Surgical Toolkit (OPTI-Surg)||Cancer Prevention and Control CIRB||Available to Open|
|A031704||Alliance||PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221602||Alliance||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Cancer Prevention and Control CIRB||Available to Open|
|A011202||Alliance||A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|